You are here: Industry Insights > Pfizer

News List

Gemphire cuts 33% of staff, including CFO, CMO fiercebiotech
September 27, 2018
The FDA placed a partial clinical hold on gemcabene in 2004, requesting preclinical data to move forward with an end of phase 2 meeting in dyslipidemia indications.
Immutep collaborates with Merck, Pfizer for Efti biospectrum
September 26, 2018
The clinical trial will evaluate the clinical benefits of releasing the brakes and pushing the accelerator of the body’s immune system at two different positions in the cancer immunity cycle.
Pfizer Granted FDA Breakthrough Therapy for 20-Valent Pneumococcal Conjugate Vaccine americanpharmaceuticalreview
September 21, 2018
Pfizer announced its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the prevention of invasive disease and pneumonia caused by Streptoc
Pfizer ends two Duchenne muscular dystrophy drug trials pharmatimes
September 14, 2018
Pfizer is shutting down two clinical studies assessing the anti-myostatin monoclonal antibody domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).
Merck, Pfizer intend to file Bavencio, Inlyta combo pharmatimes
September 13, 2018
Merck KGaA and Pfizer say they intend to seek US approval of a combination of Bavencio and Inlyta for kidney cancer on the back of progression-free survival data from a late-stage trial.
Gilead, Galapagos’ filgotinib aces first phase 3, suggesting it can compete with AbbVie’s upadacitinib fiercebiotech
September 13, 2018
The placebo-adjusted figures are in line with those generated in late-phase trials of rival JAK drugs.
Pfizer receives Breakthrough Therapy designation for inhibitor drug biospectrumasia
September 07, 2018
Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.
Hu-manity.co launches blockchain app to help users sell their healthcare data fiercebiotech
September 07, 2018
Built with IBM’s blockchain technology, the ledger will log people’s authorization for commercial use of their personal information and allow them to choose to share it for specific research purposes. (Pixabay / Geralt)
Pfizer terminates domagrozumab (PF-06252616) clinical studies for the treatment of Duchenne muscular dystrophy worldpharmanews
September 06, 2018
Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension
Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies americanpharmaceuticalreview
September 03, 2018
Pfizer announced it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page